Overview
- The complaint was filed Dec. 31 in Lake County and follows Indiana’s March 2024 case against other insulin makers and pharmacy benefit managers now in federal court.
- Indiana alleges Lilly worked with other manufacturers and used a distribution arrangement to drive up insulin prices over the past decade.
- The state seeks injunctive relief, damages and penalties, citing harm to nearly 700,000 residents diagnosed with diabetes.
- Rokita says he attempted to resolve the dispute over two years before suing and plans to add Indiana to ongoing multistate litigation.
- Lilly denies wrongdoing, calls the suit wasteful, highlights a $35 monthly patient cap and 70% list-price cuts, and notes similar cases have been dismissed or settled without payments.